

## **Official CV Curriculum Vitae**

**Name:** Tien-Tsai Cheng

**Citizenship:** Taiwan, R.O.C

**Office Address:** No.123 Ta Pei Rd, Niao Sung Dist., Kaohsiung City, 83301, Taiwan, R.O.C.  
Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital (CGMH) at Kaohsiung

**Language:** Chinese

**Education:** July 1978- June, 1985, Chung-Shan Medical Collage, Taichung Taiwan

**Post-Graduate Education:** Graduate Institute of Clinical Medical Sciences, Chang Gung University

**Academic Appointment:** Associate professor, School of Medicine, Chang Gung University

**Employment Record :** July 1985- June 1990, resident in internal medicine at CGMH Linco  
July 1990 till now, visiting staff in Rheumatology section at CGMH, Kaohsiung

### **Board Certification :**

- a. Rheumatology Association R.O.C Specialist, NO 121
- b. The Chinese Society of Immunology Specialist, NO 120
- c. Taiwan Society of Critical Care Medicine Specialist, NO SC0669
- d. Taiwan Society of Internal Medicine Specialist, NO 002123

### **Professional Affiliations:**

- a. Rheumatology Association R.O.C
- b. The Chinese Society of Immunology
- c. Taiwan Society of Critical Care Medicine
- d. Taiwan Society of Internal Medicine
- e. The Taiwanese Osteoporosis Association

### **Professional Activities:**

1. Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital at Kaohsiung, Director and Staff physician 1990~2002 and 2012~2015
2. Medicine intensive care unit, Chang Gung Memorial Hospital at Kaohsiung, Chief 1997~
3. The Taiwanese Osteoporosis Association, Supervisor 1998~
4. Rheumatology Association R.O.C, Director 2001~2007, 2012~2016
5. Rheumatology Association R.O.C, Secretary-general 2008~2011

## Publications

1. Predictor of Hand Radiological Progression in Patients With Rheumatoid Arthritis Receiving TNF Antagonist Therapy by Change in Grayscale Synovitis-A Preliminary Study. Chen YC, Su FM, Hsu SW, Chen JF, **Cheng TT**, Lai HM, Chiu WC. *J Clin Rheumatol*. 2017 Mar;23(2):73-76.
2. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey. Yu SF, Chen JF, Chen YC, Lai HM, Ko CH, Chiu WC, Su FM, Hsu CY, Su BY, Wu CH, **Cheng TT (corresponding author)**. *Medicine (Baltimore)*. 2017 Feb;96(5):e5959.
3. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Hsu CY, Lin MS, Su YJ, **Cheng TT**, Lin YS, Chen YC, Chiu WC, Chen TH. *Rheumatology (Oxford)*. 2016 Dec 30.
4. Is Long-Term Anti-Osteoporotic Treatment Associated with Greater Risk of Cancer in People with Severe Vertebral Fractures? A Hospital-Based Cohort Study. Chen YC, Su FM, **Cheng TT**, Lai HM, Yu SF. *J Am Geriatr Soc*. 2015 Nov;63(11):2418-9.
5. Is raloxifene associated with lower risk of mortality in postmenopausal women with vertebral fractures after vertebroplasty?: a hospital-based analysis. Su FM, Chen YC, **Cheng TT**, Lin WC, Lui CC. *BMC Musculoskelet Disord*. 2015 Aug 19;16:209.
6. Development and Validation of an Osteoporosis Self-Assessment Tool for Taiwan (OSTAi) Postmenopausal Women-A Sub-Study of the Taiwan Osteoporosis Survey (TOPS). Su FM, Liu DH, Chen JF, Yu SF, Chiu WC, Hsu CY, Ko CH, Tsai CC, **Cheng TT (corresponding author)**. *PLoS One*. 2015 Jun 18;10(6):e0130716.
7. Can antiosteoporotic therapy reduce mortality in MRI-proved acute osteoporotic vertebral fractures? Chen YC, Su FM, **Cheng TT**, Lin WC, Lui CC. *J Bone Miner Metab*. 2016 May;34(3):325-30.
8. Investigation of the caspase-dependent mitochondrial apoptotic pathway in mononuclear cells of patients with systemic Lupus erythematosus. Su YJ, **Cheng TT**, Chen CJ, Chang WN, Tsai NW, Kung CT, Wang HC, Lin WC, Huang CC, Chang YT, Su CM, Chiang YF, Cheng BC, Lin YJ, Lu CH. *J Transl Med*. 2014 Nov 6;12:303.
9. Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients. Hsu CY, Chiu WC, Chen JF, Chou CL, Su YJ, Yu SF, **Cheng TT (corresponding author)**. *J Bone Miner Metab*. 2015 Sep;33(5):577-83.
10. The association among antioxidant enzymes, autoantibodies, and disease severity score in systemic lupus erythematosus: comparison of neuropsychiatric and nonneuropsychiatric groups. Su YJ, **Cheng TT**, Chen CJ, Chiu WC, Chang WN, Tsai NW, Kung CT, Lin WC, Huang CC, Chang YT, Su CM, Chiang YF, Cheng BC, Lu CH. *Biomed Res Int*. 2014;2014:137231.
11. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Furie R, Nicholls K, **Cheng TT**, Houssiau F, Burgos-Vargas R, Chen SL, Hillson JL, Meadows-Shropshire S, Kinaszczuk M, Merrill JT. *Arthritis Rheumatol*.

- 2014 Feb;66(2):379-89.
12. EBV-encoded small RNA1 and nonresolving inflammation in rheumatoid arthritis. Chiu WC, Chen CM, **Cheng TT**, You HL, Yu SF, Weng LH, Huang HY, Huang CC, Chen CJ. *Kaohsiung J Med Sci*. 2013 Nov;29(11):606-10.
  13. The association among leukocyte apoptosis, autoantibodies and disease severity in systemic lupus erythematosus. Su YJ, **Cheng TT**, Chen CJ, Chiu WC, Hsu CY, Chang WN, Tsai NW, Kung CT, Wang HC, Lin WC, Huang CC, Chang YT, Su CM, Chiang YF, Cheng BC, Lin YJ, Lu CH. *J Transl Med*. 2013 Oct 19;11:261.
  14. Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary. Hwang JS, Chan DC, Chen JF, **Cheng TT**, Wu CH, Soong YK, Tsai KS, Yang RS. *J Bone Miner Metab*. 2014 Jan;32(1):10-6.
  15. Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review. Chiu CK, Kuo MC, Yu SF, Su BY, **Cheng TT (corresponding author)**. *BMC Musculoskelet Disord*. 2013 Sep 23;14:276.
  16. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines. **Cheng TT**, Yu SF, Hsu CY, Chen SH, Su BY, Yang TS. *Clin Ther*. 2013 Jul;35(7):1005-15.
  17. Androgen receptor genetic variants in male patients with ankylosing spondylitis in Taiwan. Yu SF, Hsu YH, **Cheng TT**, Lai HM, Chen CJ, Kang HY. *Int J Rheum Dis*. 2013 Feb;16(1):81-7. doi: 10.1111/1756-185X.12011.
  18. Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference. Yu SF, Yang TS, Chiu WC, Hsu CY, Chou CL, Su YJ, Lai HM, Chen YC, Chen CJ, **Cheng TT (corresponding author)** *J Bone Miner Metab*. 2013 May;31(3):351-9.
  19. Adherence to anti-osteoporotic regimens in a Southern Taiwanese population treated according to guidelines: a hospital-based study. Yu SF, Chou CL, Lai HM, Chen YC, Chiu CK, Kuo MC, Su YJ, Chen CJ, **Cheng TT (corresponding author)** *Int J Rheum Dis*. 2012 Jun;15(3):297-305.
  20. Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis. Lin KM, Lin JC, Tseng WY, **Cheng TT**. *J Microbiol Immunol Infect*. 2013 Feb;46(1):65-7.
  21. Gout and type 2 diabetes have a mutual inter-dependent effect on genetic risk factors and higher incidences. Lai HM, Chen CJ, Su BY, Chen YC, Yu SF, Yen JH, Hsieh MC, **Cheng TT (corresponding author)**, Chang SJ. *Rheumatology (Oxford)*. 2012 Apr;51(4):715-20.
  22. Age- and gender-related long-term renal outcome in patients with lupus nephritis. Hsu CY, Chiu WC, Yang TS, Chen CJ, Chen YC, Lai HM, Yu SF, Su YJ, Cheng TT. *Lupus*. 2011 Oct;20(11):1135-41.
  23. Urinary UMOD excretion and chronic kidney disease in gout patients: cross-sectional case-control study. Wu CH, Lee CT, Lee CH, **Cheng TT**, Chang HW, Lin E, Chuang FR,

- Yang HP, Chen YC, Wu CY, Chen CJ. Ren Fail. 2011;33(2):164-8. d
24. Unsuspected multiple myeloma presenting as Escherichia coli infectious spondylitis: a case report. Yu SF, Lui CC, Pei SN, Liu JW, **Cheng TT**. Int J Rheum Dis. 2010 Oct;13(4):e55-8.
  25. Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis. Chou CT, Tsai CY, Liang TH, Chang TM, Lai CH, Wei CC, Chen KH, Lin SC, Yu CL, Liou LB, Luo SF, Lee CS, Hsue YT, Huang CM, Chen JH, Lai NS, Cheng HH, **Cheng TT**, Lai HM, Tsai WC, Yen JH, Lu LY, Chang CP. Mod Rheumatol. 2010 Dec;20(6):580-7.
  26. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Lin HY, **Cheng TT**, Wang JH, Lee CS, Chen MH, Lei V, Lac C, Gammaitoni AR, Smugar SS, Chen WJ. Int J Rheum Dis. 2010 May;13(2):144-50.
  27. Lack of association of mannose-binding lectin gene polymorphisms with development and clinical manifestations of systemic lupus erythematosus in Chinese children. Tsai YC, Yao TC, Kuo ML, **Cheng TT**, Huang JL. Lupus. 2009 Apr;18(4):372-6.
  28. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Cohen SB, **Cheng TT**, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, Caulfield JP. Arthritis Rheum. 2009 Feb;60(2):335-44.
  29. New vertebral osteoporotic compression fractures after percutaneous vertebroplasty: retrospective analysis of risk factors. Lin WC, **Cheng TT**, Lee YC, Wang TN, Cheng YF, Lui CC, Yu CY. J Vasc Interv Radiol. 2008 Feb;19(2 Pt 1):225-31.
  30. Refractures in cemented vertebrae after percutaneous vertebroplasty: a retrospective analysis. Lin WC, Lee YC, Lee CH, Kuo YL, Cheng YF, Lui CC, **Cheng TT**. Eur Spine J. 2008 Apr;17(4):592-9.
  31. Ischemia heart disease and greater waist circumference are risk factors of renal function deterioration in male gout patients. Su BY, Lai HM, Chen CJ, Chen YC, Chiu CK, Lin KM, Yu SF, **Cheng TT (corresponding author)**. Clin Rheumatol. 2008 May;27(5):581-6.
  32. Systemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporin A: a case report. Wang SW, **Cheng TT (corresponding author)**. Lupus. 2005;14(6):483-5.
  33. Elevated serum homocysteine levels for gouty patients. **Cheng TT**, Lai HM, Chang HW, Luo SF. Clin Rheumatol. 2005 Apr;24(2):103-6.
  34. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. **Cheng TT**, Lai HM, Chiu CK, Chen YC. Clin Ther. 2004 Mar;26(3):399-406.
  35. Elevated homocysteine levels in patients with Raynaud's phenomenon secondary to systemic lupus erythematosus. **Cheng TT**, Chiu CK. Clin Rheumatol. 2002
  36. Overwhelming septic cavernous sinus thrombosis in a woman after combination of high-dose steroid and intravenous cyclophosphamide therapy for lupus nephritis. Chen YC, **Cheng TT**, Lai HM, Wu CH. Lupus. 2000;9(1):78-9.

37. CT findings at lupus mesenteric vasculitis. Ko SF, Lee TY, **Cheng TT**, Ng SH, Lai HM, Cheng YF, Tsai CC. Acta Radiol. 1997 Jan;38(1):115-20.